When was NMD Pharma founded?

NMD Pharma was founded in 2015 and raised its 1st funding round 1 year after it was founded.

Where is NMD Pharma located?

NMD Pharma is headquartered in Aarhus, Denmark. It is registered at NMD Pharma, Åbogade 15, 8200 Aarhus N, Denmark.

Who is the current CEO of NMD Pharma?

Thomas Holm Pedersen of NMD Pharma.

Which legal entities is NMD Pharma associated with?

NMD Pharma is associated with Nmd Pharma A S.

How many employees does NMD Pharma have?

As of Aug 31, 2026, the latest employee count at NMD Pharma is 88.

Is NMD Pharma a funded company?

NMD Pharma is a funded company, having raised a total of $174M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jun 02, 2016.

When was the latest funding round of NMD Pharma?

NMD Pharma's latest funding was a $***** Series B round on Nov 15, 2023, with participation from 5 investors.

Where does NMD Pharma rank among its competitors?

NMD Pharma ranks 42nd amongst 544 active competitors, of which 166 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was MapLight, which secured $150M in Aug, 2026.

Who are the top competitors of NMD Pharma?

NMD Pharma's top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, MapLight secured the most recent funding round in August, 2026.

NMD Pharma - 2026 Company Profile, Team, Funding, Competitors & Financials

NMD Pharma is a series B company based in Aarhus (Denmark), founded in 2015 by Thomas Holm Pedersen. It operates as a Developper of Ion-channel targeted drugs for treating neuromuscular synaptic disorders. NMD Pharma has raised $174M in funding from Jeito and Inkef, with a current valuation of $*****. The company has 544 active competitors, including 166 funded and 126 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.

Company Details

NMD Pharma is developing small molecule drugs for neuromuscular disorders including myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy (SMA). It is currently developing compounds that can maximize the residual muscle activity by targeting an ion channel specific to skeletal muscle fibers.

Website: www.nmdpharma.com/
Social
Registered Address: NMD Pharma, Åbogade 15, 8200 Aarhus N, Denmark

Key Metrics

Founded Year

2015

Location

Aarhus, Denmark

Stage

Series B

Total Funding

$174M in 4 rounds

Latest Funding Round

Series B, Nov 15, 2023, $*****

Investors

Jeito & 7 more

Ranked

42^nd among 544 active competitors

Employee Count

88 as on Aug 31, 2026

Similar Companies

Keros Therapeutics & 50 more

View NMD Pharma's full profile

NMD Pharma is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Nmd Pharma A S CIN: 36899069 , Denmark, Active	Dec 31, 2014	-	44 (As on Nov 30, 2024)

NMD Pharma has raised a total funding of $174M over 4 rounds. Its first funding round was on Jun 02, 2016. Its latest funding round was a Series B round on Nov 15, 2023 for $*****. 5 investors participated in its latest round. NMD Pharma has 8 institutional investors.

Here is the list of recent funding rounds of NMD Pharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 15, 2023	6079470	Series B	2871009	8642607	9801868	3105882
Feb 15, 2022	2303100	Series B	1751784	1112869	2371634	Novo Holdings & 3 more
Mar 06, 2018	7033757	Series A	1835195	9149023	Inkef	Lundbeck Foundation & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of NMD Pharma's funding rounds and investors

The founders of NMD Pharma is Thomas Holm Pedersen.

Here are the details of NMD Pharma's key team members:

Thomas Holm Pedersen: Co-Founder & CEO of NMD Pharma.

NMD Pharma's Board of Directors

NMD Pharma's board has 6 active members. Morten Døssing, Christian Ellebæk Elling, Patrick Volkert Jozef John Vink, Monique Claude Schiersing, Roel Bulthuis and Jeremy Paul Spring Horn are independent board members.

Here is the list of NMD Pharma's board of directors:

Name	Type	Representing	Status	Duration
Morten Døssing	Independent board member	-	Current	9y 6m
zjzsinh	Independent board member	-	Current	8y 9m
{hkylrv	Independent board member	-	Current	9y 8m
{{otfrv	Independent board member	-	Current	7y 3m
giduevv	Independent board member	-	Current	6y 3m
bibpnzm	Independent board member	-	Current	5y 7m

View details of NMD Pharma's Founder profiles and Board Members

NMD Pharma's employee count trend

NMD Pharma has 88 employees as of Aug 26. Here is NMD Pharma's employee count trend over the years:

Uncover NMD Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NMD Pharma include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of NMD Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Pacira 2006, Parsippany Troy Hills (United States), Public	Developer of injectable non-opioid products for post-surgical pain control	$85M	Orbimed, HBM Healthcare Investments & 6 others	69/100
5th	AskBio 2001, Durham (United States), Acquired	Developer of AAV technologies for treating genetic and complex disorders	$235M	Vida Ventures, TPG & 4 others	68/100
6th	MapLight 2018, Redwood City (United States), Public	Developer of therapeutic for central nervous system disorders	$698M	Goldman Sachs, Cowen & 10 others	68/100
7th	Neurocrine 1992, San Diego (United States), Acquired	Developer of small molecule therapeutics for endocrine and CNS disorders	$10M	Venrock, BB Biotech & 6 others	68/100
8th	Neumora 2020, Watertown (United States), Public	Developer of precision medicines for neuropsychiatric disorders and neurodegenerative disorders	$612M	Arch Venture Partners, Mubadala & 19 others	67/100
9th	Keros Therapeutics 2016, Lexington (United States), Public	Developer of small molecules to treat hematologic and musculoskeletal disorders	$90M	Foresite Capital, Pontifax & 9 others	66/100
10th	Septerna 2020, San Bruno (United States), Public	Developer of GPCR drug discovery platform for multiple diseases	$250M	RA Capital Management, Third Rock Ventures ... & 14 others	66/100
42nd	NMD Pharma 2015, Aarhus (Denmark), Series B	Developper of Ion-channel targeted drugs for treating neuromuscular synaptic disorders	$174M	Lundbeck Foundation, Roche Enterprises & 6 others	58/100